Health-related quality of life among patients with metastatic prostate cancer
Health-related quality of life among patients with metastatic prostate cancer
复制标题
DOI：
10.1016/s0090-4295(96)00485-2
复制
发表时间：
1997-02-01
期刊：
影响因子：
2.1
通讯作者：
Ware, JE
中科院分区：
文献类型：
--
作者：
Albertsen, PC;Aaronson, NK;Ware, JE
目标。评估和比较接受促黄体生成素释放激素（LHRH）激动剂和氟他胺治疗的缓解期晚期前列腺癌患者或进展期前列腺癌患者的双重生活。我们对113名转移性前列腺癌患者进行了一项横断面调查，以测量与健康相关的生活质量，其中60人处于缓解期，53人处于疾病进展期，使用了一系列问卷调查，包括欧洲癌症研究和治疗组织生活质量问卷- c30、医疗结果研究简短健康调查SF-36和前列腺癌特异性模块结果。与疾病进展患者相比，接受LHRH激动剂和氟他胺治疗的缓解期患者的生活质量明显更好（P < 0.011）。与激素抗性疾病的患者相比，患有激素敏感性癌症的男性身体疼痛明显减少，精力更充沛，社交活动更多，心理健康状况更好。两组之间在治疗相关问题如腹泻、便秘、泌尿系统症状、性功能、性满足或潮热方面没有差异，尽管处于缓解期的男性比处于疾病进展期的男性更倾向于评价这些项目。与疾病进展的男性相比，缓解期男性的健康相关生活质量与美国普通人群的同等标准相似，后者在所有测量领域都表现出显著的妥协。结论：接受LHRH激动剂和氟他胺治疗的缓解期患者的生活质量与没有前列腺癌的匹配男性人群没有区别，其生活质量明显优于雄激素抵抗性疾病的男性。在对全雄激素消融术有反应的患者中，氟他胺和LHRH激动剂为受者提供了显著的、可测量的益处，与任何可能的寿命改善无关。Elsevier Science Inc.版权所有
Objectives. To assess and compare the duality of life of men with advanced prostate cancer who are in remission receiving treatment with a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide or who are in progression.Methods. We conducted a cross-sectional survey to measure health-related quality of life in a cohort of 113 patients with metastatic prostate cancer, 60 in remission and 53 with disease progression, using a battery of questionnaires, including the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, the Medical Outcomes Study Short Form Health Survey SF-36, and a prostate cancer-specific module.Results. Patients in remission receiving an LHRH agonist and flutamide reported a significantly better quality of life compared with patients with disease progression (P < 0.011). Men with hormone-sensitive cancer had significantly less bodily pain, more vitality, more social interactions, and better mental health than patients with hormone-resistant disease. No differences were noted between the two groups concerning treatment-related problems such as diarrhea, constipation, urinary symptoms, sexual function, sexual satisfaction, or hot flashes, although men in remission tended to rate each of these items more favorably than did men with disease progression. Men in remission have a health-related quality of life that is similar to an equivalent norm for men in the United States general population as compared with men with disease progression, who demonstrate significant compromise in all domains measured.Conclusions, Patients in remission receiving an LHRH agonist and flutamide have a quality of life that is indistinguishable from a matched male population without prostate cancer and a quality of life significantly better than that of men with androgen-resistant disease. Among patients who respond to total androgen ablation, flutamide and an LHRH agonist provide significant, measurable benefits to recipients independent of any possible improvement in longevity. Copyright 1997 by Elsevier Science Inc.